Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Allena Pharmaceuticals Inc. - news published 30 - readings 817

BACK

Allena Pharmaceuticals Inc.

SEC Staff Action Order - Form SEC STAFF ACTION

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Allena Pharmaceuticals Inc. published this content on 12 June 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 12 June 2023 18:01:34 UTC .

12.06.2023

Allena Pharmaceuticals Inc.

Late Filing Notice - Form NT 10-Q

NT 10-Q SEC FILE NUMBER 001-38268 CUSIP NUMBER 018119107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on ...

14.11.2022

Allena Pharmaceuticals Inc.

Failure to Satisfy Listing Rule - Form 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 06, 2022 Allena Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38268 45-2729920 (State or Other Jurisdict ...

07.09.2022

Allena Pharmaceuticals Inc.

Termination of a Material Definitive Agreement - Form 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2022 (August 29, 2022) Allena Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38268 45-2729920 (State o ...

02.09.2022

Allena Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investmen ...

02.02.2022

Allena Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

02.02.2022

Allena Pharmaceuticals Inc.

Management Change/Compensation - Form 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2022 (January 28, 2022) Allena Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38268 45-2729920 (State o ...

02.02.2022

Allena Pharmaceuticals Inc.

Allena's KOL Event to Review Topline ALLN-346 Phase 2a Data

ALLN-346 for the Treatment of Gout in Chronic Kidney Disease KOL webinar hosted by Allena Pharmaceuticals, Inc. (Nasdaq: ALNA) January 4, 2022 8:00 am ET Allena Pharmaceuticals, Inc. These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should,&qu ...

05.01.2022

Allena Pharmaceuticals Inc.

Supplemental Prospectus (Form 424B5)

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255837 PROSPECTUS SUPPLEMENT (To prospectus effective May 12, 2021) $50,000,000 of Common Stock Allena Pharmaceuticals, Inc. This prospectus supplement relates to the issuance and sale of up to $50,000,000 of our common stock from time to time through or to our sales agent, B. Riley Securities, Inc. ...

23.12.2021

Allena Pharmaceuticals Inc.

Supplemental Prospectus (Form 424B5)

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255837 PROSPECTUS SUPPLEMENT (To prospectus effective May 12, 2021) 10,678,872 Shares of Common Stock Underlying Warrants Allena Pharmaceuticals, Inc. This prospectus supplement relates to the issuance of 10,678,872 shares of our common stock, par value $0.001 per share (the "Common Stock") ...

23.12.2021

Allena Pharmaceuticals Inc.

Material Definitive Agreement - Form 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2021 Allena Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-38268 45-2729920 (State or other jurisdicti ...

23.12.2021

Allena Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

17.11.2021

Allena Pharmaceuticals Inc.

Allena Corporate Presentation November 2021

Corporate Presentation November 2021 Allena Pharmaceuticals, Inc. These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "pr ...

16.11.2021

Allena Pharmaceuticals Inc.

Quarterly Report (Form 10-Q)

10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ ...

12.11.2021

Allena Pharmaceuticals Inc.

Amendment to Quarterly Report (Form 10-Q/A)

10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

12.11.2021

Allena Pharmaceuticals Inc. - news published 30 - readings 817

Allena Pharmaceuticals Inc.

SEC Staff Action Order - Form SEC STAFF ACTION

Allena Pharmaceuticals Inc.

Late Filing Notice - Form NT 10-Q

Allena Pharmaceuticals Inc.

Failure to Satisfy Listing Rule - Form 8-K

Allena Pharmaceuticals Inc.

Termination of a Material Definitive Agreement - Form 8-K

Allena Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Allena Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Allena Pharmaceuticals Inc.

Management Change/Compensation - Form 8-K

Allena Pharmaceuticals Inc.

Allena's KOL Event to Review Topline ALLN-346 Phase 2a Data

Allena Pharmaceuticals Inc.

Supplemental Prospectus (Form 424B5)

Allena Pharmaceuticals Inc.

Supplemental Prospectus (Form 424B5)

Allena Pharmaceuticals Inc.

Material Definitive Agreement - Form 8-K

Allena Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Allena Pharmaceuticals Inc.

Allena Corporate Presentation November 2021

Allena Pharmaceuticals Inc.

Quarterly Report (Form 10-Q)

Allena Pharmaceuticals Inc.

Amendment to Quarterly Report (Form 10-Q/A)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member